# OnCo record nct06679101 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06679101/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06679101", "NCT06679101" ;
  schema:name "A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethas"@en ;
  schema:alternateName "DREAMM-10"@en ;
  schema:description "A phase 3 trial of Belantamab mafodotin, Lenalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06679101/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06679101> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-12-16" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-transplant-ineligible/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/antiemetic-therapy/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:drugs <https://onco.cc/drugs/belantamab-mafodotin/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/daratumumab/> ;
  onco:companies <https://onco.cc/companies/gsk/> .